{"success":true,"data":{"pressRelease":{"id":"54069","rtpr_id":"nBw52kNnya","ticker":"ALMKT","exchange":"Euronext Paris","all_tickers":["ALMKT"],"title":"Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital","author":"Business Wire","published_at":"2026-06-03T16:00:00.486Z","article_body":"Mauna Kea Technologies: Monthly Information Regarding the Total Number of\nVoting Rights and Shares Comprising the Share Capital\n\nArticle L233-8-II of the Commercial Code\n\nArticle 223-16 of the General Regulations of the AMF\n\nRegulatory News:\n\nMauna Kea Technologies (Paris:ALMKT):\n\nListing: Euronext Growth Paris\n\nISIN code: FR0010609263, Ticker: ALMKT\n\nWebsite: www.maunakeatech.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.maunakeatech.com&esheet=54546926&newsitemid=20260603599338&lan=en-US&anchor=www.maunakeatech.com&index=1&md5=9b01fdd455bfe00e57d983bfc5c441f3)\n Date          Number of shares comprising  Total number of voting rights     \n               \nthe capital in circulation                                    \n               Gross Total( (1))                             Net Total( (2))  \n May 31, 2026  194,447,724                  195,532,591      195,532,591      \n\n\n((1)) The gross number of voting rights (or \"theoretical\" voting rights)\nserves as the basis for calculating the thresholds. In accordance with Article\n223-11 of the General Regulations of the AMF, this number is calculated on the\nbasis of all shares carrying voting rights, including shares without voting\nrights.\n\n((2)) The net number of voting rights (or voting rights \"exercisable in\nGeneral Meeting\") is calculated without considering the shares with suspended\nvoting rights. It is published for proper public information in accordance\nwith the AMF recommendation of July 17, 2007.\n\nAbout Mauna Kea Technologies\n\nMauna Kea Technologies is a global medical device company that manufactures\nand sells Cellvizio®, the real-time in vivo cellular imaging platform. This\ntechnology uniquely delivers in vivo cellular visualization which enables\nphysicians to monitor the progression of disease over time, assess\npoint-in-time reactions as they happen in real time, classify indeterminate\nareas of concern, and guide surgical interventions. The Cellvizio(®) platform\nis used globally across a wide range of medical specialties and is making a\ntransformative change in the way physicians diagnose and treat patients. For\nmore information, visit www.maunakeatech.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.maunakeatech.com&esheet=54546926&newsitemid=20260603599338&lan=en-US&anchor=www.maunakeatech.com&index=2&md5=991db398a2dcd87d57a166ee3f334ab6)\n.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260603599338/en/\n(https://www.businesswire.com/news/home/20260603599338/en/)\n\nMauna Kea Technologies \n\ninvestors@maunakeatech.com \n(mailto:investors@maunakeatech.com) \n\n\nNewCap - Investor Relations \n\nThomas Grojean\n\n+33 (0)1 44 71 94 94\n\nmaunakea@newcap.eu (mailto:maunakea@newcap.eu)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw52kNnya","title":"Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital","author":"Business Wire","ticker":"ALMKT","created":"2026-06-03T16:00:00.486Z","tickers":["ALMKT"],"exchange":"Euronext Paris","article_body":"Mauna Kea Technologies: Monthly Information Regarding the Total Number of\nVoting Rights and Shares Comprising the Share Capital\n\nArticle L233-8-II of the Commercial Code\n\nArticle 223-16 of the General Regulations of the AMF\n\nRegulatory News:\n\nMauna Kea Technologies (Paris:ALMKT):\n\nListing: Euronext Growth Paris\n\nISIN code: FR0010609263, Ticker: ALMKT\n\nWebsite: www.maunakeatech.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.maunakeatech.com&esheet=54546926&newsitemid=20260603599338&lan=en-US&anchor=www.maunakeatech.com&index=1&md5=9b01fdd455bfe00e57d983bfc5c441f3)\n Date          Number of shares comprising  Total number of voting rights     \n               \nthe capital in circulation                                    \n               Gross Total( (1))                             Net Total( (2))  \n May 31, 2026  194,447,724                  195,532,591      195,532,591      \n\n\n((1)) The gross number of voting rights (or \"theoretical\" voting rights)\nserves as the basis for calculating the thresholds. In accordance with Article\n223-11 of the General Regulations of the AMF, this number is calculated on the\nbasis of all shares carrying voting rights, including shares without voting\nrights.\n\n((2)) The net number of voting rights (or voting rights \"exercisable in\nGeneral Meeting\") is calculated without considering the shares with suspended\nvoting rights. It is published for proper public information in accordance\nwith the AMF recommendation of July 17, 2007.\n\nAbout Mauna Kea Technologies\n\nMauna Kea Technologies is a global medical device company that manufactures\nand sells Cellvizio®, the real-time in vivo cellular imaging platform. This\ntechnology uniquely delivers in vivo cellular visualization which enables\nphysicians to monitor the progression of disease over time, assess\npoint-in-time reactions as they happen in real time, classify indeterminate\nareas of concern, and guide surgical interventions. The Cellvizio(®) platform\nis used globally across a wide range of medical specialties and is making a\ntransformative change in the way physicians diagnose and treat patients. For\nmore information, visit www.maunakeatech.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.maunakeatech.com&esheet=54546926&newsitemid=20260603599338&lan=en-US&anchor=www.maunakeatech.com&index=2&md5=991db398a2dcd87d57a166ee3f334ab6)\n.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260603599338/en/\n(https://www.businesswire.com/news/home/20260603599338/en/)\n\nMauna Kea Technologies \n\ninvestors@maunakeatech.com \n(mailto:investors@maunakeatech.com) \n\n\nNewCap - Investor Relations \n\nThomas Grojean\n\n+33 (0)1 44 71 94 94\n\nmaunakea@newcap.eu (mailto:maunakea@newcap.eu)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-06-03T16:00:00.729239123Z","server_sent_at_ms":1780502400729},"received_at":"2026-06-03T16:00:00.939Z","source_url":"https://www.businesswire.com/news/home/20260603599338/en/"},"analysis":{"id":"43500","press_release_id":"54069","analysis_json":{"industry":{"label":"Medical Devices","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Mauna Kea Technologies filed its mandatory monthly regulatory disclosure regarding share capital and voting rights as of May 31, 2026.\n\nThe company reported 194,447,724 shares in circulation, with both gross and net voting rights totaling 195,532,591.\n\nThis filing is a routine compliance requirement for companies listed on Euronext Growth Paris and contains no new operational or financial information.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine regulatory filing; no new material information for investors."},"keyFigures":{"customDimensions":{"net_voting_rights":195532591,"shares_outstanding":194447724,"gross_voting_rights":195532591}},"quotedText":"Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio®, the real-time in vivo cellular imaging platform.","namedEntities":{"people":[{"name":"Thomas Grojean","role":"Investor Relations"}],"products":["Cellvizio"],"companies":[{"name":"Mauna Kea Technologies","ticker":"ALMKT","relationship":"filer"},{"name":"NewCap","relationship":"investor relations firm"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"This is a mandatory regulatory disclosure of share count and voting rights for a French-listed company. It contains no new business developments, financial results, or strategic announcements."},"tickerRelevance":{"others":[],"primary":"ALMKT"},"globalImportance":5,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"routine_regulatory_filing","householdBrandBoost":0,"marketCapAdjustment":"low"}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Mauna Kea Technologies filed its mandatory monthly regulatory disclosure regarding share capital and voting rights as of May 31, 2026.\n\nThe company reported 194,447,724 shares in circulation, with both gross and net voting rights totaling 195,532,591.\n\nThis filing is a routine compliance requirement for companies listed on Euronext Growth Paris and contains no new operational or financial information.","key_figures":{"customDimensions":{"net_voting_rights":195532591,"shares_outstanding":194447724,"gross_voting_rights":195532591}},"named_entities":{"people":[{"name":"Thomas Grojean","role":"Investor Relations"}],"products":["Cellvizio"],"companies":[{"name":"Mauna Kea Technologies","ticker":"ALMKT","relationship":"filer"},{"name":"NewCap","relationship":"investor relations firm"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-04T07:10:27.764Z","global_importance":5,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap","eventGravity":"routine_regulatory_filing","householdBrandBoost":0,"marketCapAdjustment":"low"}},"durationMs":34682,"modelName":"george-droid-qwen-72b"}}